ID   PLAT3_RAT               Reviewed;         160 AA.
AC   P53817; B7X6T2;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-SEP-2009, sequence version 2.
DT   02-OCT-2024, entry version 135.
DE   RecName: Full=Phospholipase A and acyltransferase 3 {ECO:0000305};
DE            EC=2.3.1.- {ECO:0000269|PubMed:17158102, ECO:0000269|PubMed:19047760};
DE            EC=3.1.1.32 {ECO:0000269|PubMed:19047760};
DE            EC=3.1.1.4 {ECO:0000269|PubMed:19047760};
DE   AltName: Full=Group XVI phospholipase A2 {ECO:0000312|RGD:2829};
DE   AltName: Full=H-rev 107 protein homolog {ECO:0000250|UniProtKB:P53816};
DE   AltName: Full=HRAS-like suppressor 3 {ECO:0000250|UniProtKB:P53816};
DE            Short=HRSL3 {ECO:0000250|UniProtKB:P53816};
DE   AltName: Full=Rat LRAT-like protein-3 {ECO:0000303|PubMed:17158102};
DE            Short=RLP-3 {ECO:0000303|PubMed:17158102};
GN   Name=Plaat3 {ECO:0000312|RGD:2829};
GN   Synonyms=H-rev107 {ECO:0000250|UniProtKB:P53816},
GN   Hrasls3 {ECO:0000250|UniProtKB:P53816},
GN   Hrev107 {ECO:0000250|UniProtKB:P53816}, Pla2g16 {ECO:0000312|RGD:2829},
GN   Rlp-3 {ECO:0000303|PubMed:17158102};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=8290259;
RA   Hajnal A., Klemenz R., Schaefer R.;
RT   "Subtraction cloning of H-rev107, a gene specifically expressed in H-ras
RT   resistant fibroblasts.";
RL   Oncogene 9:479-490(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Morishita J., Okamoto Y., Jin X.H., Tsuboi K., Ueda N.;
RT   "Purification and characterization of LRAT-like protein 3.";
RL   Submitted (MAR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=17158102; DOI=10.1074/jbc.m606369200;
RA   Jin X.H., Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N.;
RT   "Discovery and characterization of a Ca2+-independent
RT   phosphatidylethanolamine N-acyltransferase generating the anandamide
RT   precursor and its congeners.";
RL   J. Biol. Chem. 282:3614-3623(2007).
RN   [5]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=18614531; DOI=10.1074/jbc.m804146200;
RA   Duncan R.E., Sarkadi-Nagy E., Jaworski K., Ahmadian M., Sul H.S.;
RT   "Identification and functional characterization of adipose-specific
RT   phospholipase A2 (AdPLA).";
RL   J. Biol. Chem. 283:25428-25436(2008).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-21 AND CYS-111.
RX   PubMed=19047760; DOI=10.1194/jlr.m800453-jlr200;
RA   Uyama T., Morishita J., Jin X.H., Okamoto Y., Tsuboi K., Ueda N.;
RT   "The tumor suppressor gene H-Rev107 functions as a novel Ca2+-independent
RT   cytosolic phospholipase A1/2 of the thiol hydrolase type.";
RL   J. Lipid Res. 50:685-693(2009).
CC   -!- FUNCTION: Exhibits both phospholipase A1/2 and acyltransferase
CC       activities (PubMed:19047760). Shows phospholipase A1 (PLA1) and A2
CC       (PLA2), ccatalyzing the calcium-independent release of fatty acids from
CC       the sn-1 or sn-2 position of glycerophospholipids (PubMed:19047760).
CC       For most substrates, PLA1 activity is much higher than PLA2 activity
CC       (By similarity). Shows O-acyltransferase activity, catalyzing the
CC       transfer of a fatty acyl group from glycerophospholipid to the hydroxyl
CC       group of lysophospholipid (By similarity). Shows N-acyltransferase
CC       activity, catalyzing the calcium-independent transfer of a fatty acyl
CC       group at the sn-1 position of phosphatidylcholine (PC) and other
CC       glycerophospholipids to the primary amine of phosphatidylethanolamine
CC       (PE), forming N-acylphosphatidylethanolamine (NAPE), which serves as
CC       precursor for N-acylethanolamines (NAEs) (PubMed:17158102,
CC       PubMed:19047760). Exhibits high N-acyltransferase activity and low
CC       phospholipase A1/2 activity (By similarity). Required for complete
CC       organelle rupture and degradation that occur during eye lens terminal
CC       differentiation, when fiber cells that compose the lens degrade all
CC       membrane-bound organelles in order to provide lens with transparency to
CC       allow the passage of light. Organelle membrane degradation is probably
CC       catalyzed by the phospholipase activity (By similarity). Plays a role
CC       in phospholipid metabolism and adipogenesis.
CC       {ECO:0000250|UniProtKB:P53816, ECO:0000250|UniProtKB:Q8R3U1,
CC       ECO:0000269|PubMed:17158102, ECO:0000269|PubMed:19047760}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-
CC         glycero-3-phosphocholine + a fatty acid + H(+); Xref=Rhea:RHEA:15801,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:57643, ChEBI:CHEBI:58168; EC=3.1.1.4;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:15802;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 2-acyl-sn-
CC         glycero-3-phosphocholine + a fatty acid + H(+); Xref=Rhea:RHEA:18689,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:57643, ChEBI:CHEBI:57875; EC=3.1.1.32;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18690;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphocholine + H2O = 1-
CC         hexadecanoyl-sn-glycero-3-phosphocholine + H(+) + hexadecanoate;
CC         Xref=Rhea:RHEA:41223, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:72998, ChEBI:CHEBI:72999;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41224;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphocholine + H2O = 2-
CC         hexadecanoyl-sn-glycero-3-phosphocholine + H(+) + hexadecanoate;
CC         Xref=Rhea:RHEA:40487, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:72999, ChEBI:CHEBI:76078;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40488;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine
CC         + H2O = 2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + H(+) +
CC         hexadecanoate; Xref=Rhea:RHEA:38783, ChEBI:CHEBI:7896,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:73001,
CC         ChEBI:CHEBI:76071; Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38784;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine
CC         + H2O = (9Z)-octadecenoate + 1-hexadecanoyl-sn-glycero-3-
CC         phosphocholine + H(+); Xref=Rhea:RHEA:38779, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30823, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:73001; Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38780;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphocholine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-
CC         hexadecanoyl-sn-glycero-3-phosphocholine + H(+);
CC         Xref=Rhea:RHEA:40427, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:32395, ChEBI:CHEBI:72998, ChEBI:CHEBI:73003;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40428;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphocholine + H2O = 2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-
CC         glycero-3-phosphocholine + H(+) + hexadecanoate;
CC         Xref=Rhea:RHEA:40571, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:73003, ChEBI:CHEBI:76079;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40572;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
CC         phosphoethanolamine + H2O = (9Z,12Z)-octadecadienoate + 1-
CC         hexadecanoyl-sn-glycero-3-phosphoethanolamine + H(+);
CC         Xref=Rhea:RHEA:40815, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30245, ChEBI:CHEBI:73004, ChEBI:CHEBI:73008;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40816;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
CC         phosphoethanolamine + H2O = 2-(9Z,12Z)-octadecadienoyl-sn-glycero-3-
CC         phosphoethanolamine + H(+) + hexadecanoate; Xref=Rhea:RHEA:45164,
CC         ChEBI:CHEBI:7896, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:73008, ChEBI:CHEBI:76090;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45165;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphoethanolamine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-
CC         hexadecanoyl-sn-glycero-3-phosphoethanolamine + H(+);
CC         Xref=Rhea:RHEA:40431, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:32395, ChEBI:CHEBI:73004, ChEBI:CHEBI:73009;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40432;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphoethanolamine + H2O = 2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-
CC         glycero-3-phosphoethanolamine + H(+) + hexadecanoate;
CC         Xref=Rhea:RHEA:41348, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:73009, ChEBI:CHEBI:76091;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41349;
CC         Evidence={ECO:0000269|PubMed:19047760};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexanoyl-2-acyl-sn-glycero-3-phosphocholine + H2O = a 2-
CC         acyl-sn-glycero-3-phosphocholine + H(+) + hexanoate;
CC         Xref=Rhea:RHEA:53496, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17120, ChEBI:CHEBI:57875, ChEBI:CHEBI:137403;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53497;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexanoyl-2-acyl-sn-glycero-3-phosphocholine + H2O = 1-
CC         hexanoyl-sn-glycero-3-phosphocholine + a fatty acid + H(+);
CC         Xref=Rhea:RHEA:53500, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:28868, ChEBI:CHEBI:78215, ChEBI:CHEBI:137403;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53501;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine + 1-(9Z-
CC         octadecenoyl)-2-hexadecanoyl-sn-glycero-3-phosphocholine = 1,2-
CC         diheptadecanoyl-sn-glycero-3-phospho-N-hexadecanoyl-ethanolamine + 1-
CC         (9Z-octadecenoyl)-sn-glycero-3-phosphocholine + H(+);
CC         Xref=Rhea:RHEA:53524, ChEBI:CHEBI:15378, ChEBI:CHEBI:28610,
CC         ChEBI:CHEBI:74667, ChEBI:CHEBI:138218, ChEBI:CHEBI:138220;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53525;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine + 1-(9Z-
CC         octadecenoyl)-2-hexadecanoyl-sn-glycero-3-phosphocholine = 1,2-
CC         diheptadecanoyl-sn-glycero-3-phospho-N-(9Z-octadecenoyl)-ethanolamine
CC         + 2-hexadecanoyl-sn-glycero-3-phosphocholine + H(+);
CC         Xref=Rhea:RHEA:53528, ChEBI:CHEBI:15378, ChEBI:CHEBI:74667,
CC         ChEBI:CHEBI:76078, ChEBI:CHEBI:138218, ChEBI:CHEBI:138222;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53529;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexanoyl-sn-glycero-3-phosphoethanolamine + 2-heptanoyl-
CC         sn-glycero-3-phosphocholine = 1-hexanoyl-2-heptanoyl-sn-glycero-3-
CC         phosphocholine + hexanoyl-sn-glycero-3-phosphoethanolamine;
CC         Xref=Rhea:RHEA:54544, ChEBI:CHEBI:138197, ChEBI:CHEBI:138216,
CC         ChEBI:CHEBI:138266, ChEBI:CHEBI:138267;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54545;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine +
CC         H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) +
CC         octadecanoate; Xref=Rhea:RHEA:56432, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:25629, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:73000; Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:56433;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine +
CC         H2O = 2-octadecanoyl-sn-glycero-3-phosphocholine + H(+) +
CC         hexadecanoate; Xref=Rhea:RHEA:56436, ChEBI:CHEBI:7896,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:73000,
CC         ChEBI:CHEBI:76076; Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:56437;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-hexadecanoyl-sn-glycero-3-phosphocholine +
CC         H2O = 1-octadecanoyl-sn-glycero-3-phosphocholine + H(+) +
CC         hexadecanoate; Xref=Rhea:RHEA:56440, ChEBI:CHEBI:7896,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:73858,
CC         ChEBI:CHEBI:75026; Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:56441;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-hexadecanoyl-sn-glycero-3-phosphocholine +
CC         H2O = 2-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) +
CC         octadecanoate; Xref=Rhea:RHEA:56444, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:25629, ChEBI:CHEBI:75026,
CC         ChEBI:CHEBI:76078; Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:56445;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
CC         phosphocholine + H2O = (9Z,12Z)-octadecadienoate + 1-hexadecanoyl-sn-
CC         glycero-3-phosphocholine + H(+); Xref=Rhea:RHEA:40811,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30245,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:73002;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40812;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
CC         phosphocholine + H2O = 2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
CC         phosphocholine + H(+) + hexadecanoate; Xref=Rhea:RHEA:40971,
CC         ChEBI:CHEBI:7896, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:73002, ChEBI:CHEBI:76084;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40972;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + H2O =
CC         (9Z)-octadecenoate + 2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine
CC         + H(+); Xref=Rhea:RHEA:56448, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30823, ChEBI:CHEBI:74669, ChEBI:CHEBI:76071;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:56449;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphocholine + H2O = H(+) +
CC         hexadecanoate + hexadecanoyl-sn-glycero-3-phosphocholine;
CC         Xref=Rhea:RHEA:41384, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:64563, ChEBI:CHEBI:72999;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41385;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + H2O =
CC         (9Z)-octadecenoate + 1-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine
CC         + H(+); Xref=Rhea:RHEA:40923, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:28610, ChEBI:CHEBI:30823, ChEBI:CHEBI:74669;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40924;
CC         Evidence={ECO:0000250|UniProtKB:P53816};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine +
CC         1,2-dihexadecanoyl-sn-glycero-3-phosphocholine = H(+) + hexadecanoyl-
CC         sn-glycero-3-phosphocholine + N-hexadecanoyl-1,2-di-(9Z-
CC         octadecenoyl)-sn-glycero-3-phosphoethanolamine; Xref=Rhea:RHEA:41360,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:64563, ChEBI:CHEBI:72999,
CC         ChEBI:CHEBI:74986, ChEBI:CHEBI:78097;
CC         Evidence={ECO:0000269|PubMed:17158102};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41361;
CC         Evidence={ECO:0000269|PubMed:17158102};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine +
CC         H2O = (9Z,12Z)-octadecadienoate + 1-(9Z,12Z)-octadecadienoyl-sn-
CC         glycero-3-phosphocholine + H(+); Xref=Rhea:RHEA:56428,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28733,
CC         ChEBI:CHEBI:30245, ChEBI:CHEBI:42027;
CC         Evidence={ECO:0000250|UniProtKB:Q8R3U1};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:56429;
CC         Evidence={ECO:0000250|UniProtKB:Q8R3U1};
CC   -!- SUBUNIT: Interacts with PPP2R1A; this interaction might decrease PP2A
CC       activity. {ECO:0000250|UniProtKB:P53816}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:8290259};
CC       Single-pass membrane protein {ECO:0000255}. Cytoplasm
CC       {ECO:0000269|PubMed:8290259}. Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:Q8R3U1}. Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:8290259}. Peroxisome membrane
CC       {ECO:0000250|UniProtKB:Q8R3U1}. Mitochondrion membrane
CC       {ECO:0000250|UniProtKB:Q8R3U1}; Single-pass membrane protein
CC       {ECO:0000305}. Nucleus envelope {ECO:0000250|UniProtKB:Q8R3U1}.
CC       Lysosome membrane {ECO:0000250|UniProtKB:Q8R3U1}; Single-pass membrane
CC       protein {ECO:0000305}. Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:Q8R3U1}; Single-pass membrane protein
CC       {ECO:0000305}. Note=During eye lens differentiation, recruited from the
CC       cytosol to various organelles, including mitochondria, endoplasmic
CC       reticulum, nuclear envelope and lysosomes, immediately before organelle
CC       degradation. This translocation is triggered by organelle membrane
CC       damage and requires the C-terminal transmembrane domain.
CC       {ECO:0000250|UniProtKB:Q8R3U1}.
CC   -!- TISSUE SPECIFICITY: Specifically expressed in H-ras resistant
CC       fibroblasts. {ECO:0000269|PubMed:18614531, ECO:0000269|PubMed:8290259}.
CC   -!- INDUCTION: Induced during preadipocyte differentiation into adipocytes.
CC       {ECO:0000269|PubMed:18614531}.
CC   -!- DOMAIN: The C-terminal transmembrane domain is required for the
CC       targeting of the protein to damaged organelles.
CC       {ECO:0000250|UniProtKB:Q8R3U1}.
CC   -!- SIMILARITY: Belongs to the H-rev107 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X76453; CAA53991.1; -; mRNA.
DR   EMBL; AB298805; BAH08634.1; -; mRNA.
DR   EMBL; CH473953; EDM12684.1; -; Genomic_DNA.
DR   EMBL; CH473953; EDM12685.1; -; Genomic_DNA.
DR   PIR; S42794; S42794.
DR   RefSeq; NP_058756.2; NM_017060.2.
DR   AlphaFoldDB; P53817; -.
DR   SMR; P53817; -.
DR   STRING; 10116.ENSRNOP00000038045; -.
DR   SwissLipids; SLP:000001906; -.
DR   PhosphoSitePlus; P53817; -.
DR   PaxDb; 10116-ENSRNOP00000038045; -.
DR   GeneID; 24913; -.
DR   KEGG; rno:24913; -.
DR   UCSC; RGD:2829; rat.
DR   AGR; RGD:2829; -.
DR   CTD; 11145; -.
DR   RGD; 2829; Plaat3.
DR   VEuPathDB; HostDB:ENSRNOG00000021206; -.
DR   eggNOG; ENOG502S0JN; Eukaryota.
DR   InParanoid; P53817; -.
DR   OrthoDB; 3059772at2759; -.
DR   PhylomeDB; P53817; -.
DR   TreeFam; TF330836; -.
DR   BRENDA; 3.1.1.32; 5301.
DR   Reactome; R-RNO-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-RNO-1482801; Acyl chain remodelling of PS.
DR   Reactome; R-RNO-1482839; Acyl chain remodelling of PE.
DR   Reactome; R-RNO-1482922; Acyl chain remodelling of PI.
DR   PRO; PR:P53817; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Proteomes; UP000234681; Chromosome 1.
DR   Bgee; ENSRNOG00000021206; Expressed in duodenum and 20 other cell types or tissues.
DR   ExpressionAtlas; P53817; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005764; C:lysosome; ISS:UniProtKB.
DR   GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005635; C:nuclear envelope; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:RGD.
DR   GO; GO:0005778; C:peroxisomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005777; C:peroxisome; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0052740; F:1-acyl-2-lysophosphatidylserine acylhydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008289; F:lipid binding; ISO:RGD.
DR   GO; GO:0016410; F:N-acyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0052739; F:phosphatidylserine 1-acylhydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008970; F:phospholipase A1 activity; IDA:UniProtKB.
DR   GO; GO:0004623; F:phospholipase A2 activity; IDA:UniProtKB.
DR   GO; GO:0004620; F:phospholipase activity; ISO:RGD.
DR   GO; GO:0046485; P:ether lipid metabolic process; ISS:UniProtKB.
DR   GO; GO:0070306; P:lens fiber cell differentiation; ISS:UniProtKB.
DR   GO; GO:0016042; P:lipid catabolic process; ISS:UniProtKB.
DR   GO; GO:0030397; P:membrane disassembly; ISS:UniProtKB.
DR   GO; GO:0070292; P:N-acylphosphatidylethanolamine metabolic process; ISS:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IMP:RGD.
DR   GO; GO:1903008; P:organelle disassembly; ISS:UniProtKB.
DR   GO; GO:0007031; P:peroxisome organization; ISS:UniProtKB.
DR   GO; GO:0008654; P:phospholipid biosynthetic process; ISO:RGD.
DR   GO; GO:0006644; P:phospholipid metabolic process; ISS:UniProtKB.
DR   GO; GO:1904177; P:regulation of adipose tissue development; ISS:UniProtKB.
DR   GO; GO:0009617; P:response to bacterium; ISO:RGD.
DR   GO; GO:0006641; P:triglyceride metabolic process; ISS:UniProtKB.
DR   Gene3D; 3.90.1720.10; endopeptidase domain like (from Nostoc punctiforme); 1.
DR   InterPro; IPR051496; H-rev107_PLA/AT.
DR   InterPro; IPR007053; LRAT_dom.
DR   PANTHER; PTHR13943; HRAS-LIKE SUPPRESSOR - RELATED; 1.
DR   PANTHER; PTHR13943:SF31; PHOSPHOLIPASE A AND ACYLTRANSFERASE 3; 1.
DR   Pfam; PF04970; LRAT; 1.
DR   PROSITE; PS51934; LRAT; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Cytoplasm; Endoplasmic reticulum; Hydrolase;
KW   Lipid degradation; Lipid metabolism; Lysosome; Membrane; Mitochondrion;
KW   Nucleus; Peroxisome; Reference proteome; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..160
FT                   /note="Phospholipase A and acyltransferase 3"
FT                   /id="PRO_0000152487"
FT   TOPO_DOM        1..131
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        132..152
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        153..160
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          11..127
FT                   /note="LRAT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01283"
FT   ACT_SITE        21
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01283,
FT                   ECO:0000305|PubMed:19047760"
FT   ACT_SITE        33
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01283"
FT   ACT_SITE        111
FT                   /note="Acyl-thioester intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01283,
FT                   ECO:0000305|PubMed:19047760"
FT   MUTAGEN         21
FT                   /note="H->L: Abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:19047760"
FT   MUTAGEN         111
FT                   /note="C->S: Abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:19047760"
FT   CONFLICT        131
FT                   /note="A -> T (in Ref. 1; CAA53991)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   160 AA;  17749 MW;  A0B32D6FA0A943A3 CRC64;
     MPIPEPKPGD LIEIFRPMYS HWAIYVGDGY VIHLAPPSEI PGAGAASIMS ALTDKAIVKK
     ELLRDVAGKD KYQVNNKHDK EYTPLPLNKI IQRAEELVGQ EVLYRLTSEN CEHFVNELRY
     GVPRSDQVRD AVKVATVTGV GLAALGLIGV MLSRNKKQKQ
//
